| __timestamp | BioMarin Pharmaceutical Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 34916000 |
| Thursday, January 1, 2015 | 402271000 | 36949000 |
| Friday, January 1, 2016 | 476593000 | 45240000 |
| Sunday, January 1, 2017 | 554336000 | 62416000 |
| Monday, January 1, 2018 | 604353000 | 81289000 |
| Tuesday, January 1, 2019 | 680924000 | 100359000 |
| Wednesday, January 1, 2020 | 737669000 | 105326000 |
| Friday, January 1, 2021 | 759375000 | 122356000 |
| Saturday, January 1, 2022 | 854009000 | 152848000 |
| Sunday, January 1, 2023 | 937300000 | 184259000 |
| Monday, January 1, 2024 | 1009025000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, BioMarin Pharmaceutical Inc. and Corcept Therapeutics Incorporated have shown contrasting approaches to handling these costs. From 2014 to 2023, BioMarin's SG&A expenses have surged by over 200%, reflecting a strategic investment in growth and expansion. In contrast, Corcept has maintained a more conservative increase of approximately 430%, indicating a focus on cost efficiency.
BioMarin's expenses peaked in 2023, reaching nearly 9.4 times their 2014 levels, while Corcept's expenses grew to about 5.3 times their initial figures. This data suggests that while BioMarin is aggressively investing in its operations, Corcept is managing its resources with a more cautious approach. Understanding these strategies provides valuable insights into each company's operational priorities and financial health.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Vericel Corporation Trends and Insights
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Corcept Therapeutics Incorporated and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Corcept Therapeutics Incorporated vs ADMA Biologics, Inc.
Breaking Down SG&A Expenses: Corcept Therapeutics Incorporated vs Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc.